Portage Biotech resumes patient enrollment for PORT-6 Phase 1b trial, showing progress

From Nasdaq: 2025-03-12 15:21:47

Portage Biotech Inc. announced the resumption of patient enrollment in the final dose escalation stage for PORT-6 within its ADPORT-601 Phase 1b clinical trial, after pausing due to funding concerns. The company plans to evaluate continuation of the study into its PORT-7 and combination arms following completion of the PORT-6 arm. This progress reaffirms confidence in the safety and therapeutic potential of PORT-6, moving closer to identifying an optimal dose range for further clinical development. CEO Alexander Pickett expressed confidence in the preliminary data and looks forward to sharing more updates later this year.



Read more at Nasdaq: Portage Biotech Resumes Patient Enrollment In Final Cohort Of Dose Escalation Stage For PORT-6